Show simple item record

dc.creatorBuvinic, Sonja
dc.date2020-05-05
dc.date.accessioned2020-10-29T13:34:44Z
dc.date.available2020-10-29T13:34:44Z
dc.identifierhttps://revistas.udec.cl/index.php/journal_of_oral_research/article/view/1014
dc.identifier.urihttps://revistaschilenas.uchile.cl/handle/2250/155762
dc.descriptionBotulinum toxin type A (BoNTA) is the most potent serotype of a group ofneurotoxins produced by obligate anaerobic bacteria Clostridium botulinum. This neurotoxin blocks the release of acetylcholine from the motor neuron, uncoupling the neuromuscular junction that results in a reversible paralysis of skeletal muscles that lasts for 4 – 6 months in humans.1 Commercially available forms of BoNTA (e.g. Botox®, Dysport®, Xeomin®) are increasingly used by dentists worldwide.1 In dentistry, conditions that affect masticator, muscles such as benign masseter hypertrophy and myofascial pain are treated with intramuscular injections of BoNTA,1,2 However, this neurotoxin is not approved for interventions in the masticatory apparatus, according to the US Food and Drug Administration (Allergan Full Prescribing Information for Botox®); as such, its clinical use is off-label.es-ES
dc.formatapplication/pdf
dc.languageeng
dc.publisherUniversidad de Concepción, Facultad de Odontologíaes-ES
dc.relationhttps://revistas.udec.cl/index.php/journal_of_oral_research/article/view/1014/1711
dc.rightsDerechos de autor 2018 Universidad de Concepciónes-ES
dc.sourceJournal of Oral Research; Vol. 7 No. 2: February; 44-46en-US
dc.sourceJournal of Oral Research; Vol. 7 Núm. 2: Febrero; 44-46es-ES
dc.source0719-2479
dc.source0719-2460
dc.subjectBotoxes-ES
dc.subjectmasticatory muscleses-ES
dc.titleMandibular bone loss: a hidden side effect of botulinum toxin type A injection in masticatory muscles.es-ES
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion


This item appears in the following Collection(s)

Show simple item record